Proactive Investors - Run By Investors For Investors

Orgenesis seals pact with Ben-Gurion University to develop dissolvable carriers for cell culturing

Under the license deal, Orgenesis will receive worldwide rights to develop and commercialize technologies utilizing the dissolvable carriers for cell culturing
A researcher in a lab
Orgenesis is focused on the development and manufacture of cell therapies for advanced medicinal products

Orgenesis Inc (NASDAQ:ORGS), a developer and manufacturer of advanced cell therapies, announced Wednesday that it has entered into a licensing and collaboration agreement with Israel-based Ben-Gurion University for the development of dissolvable carriers for cell culturing.

The technology was developed by Professor Smadar Cohen, founder and director of The Regenerative Medicine and Stem Cell (RMSC) Research Center at Ben-Gurion University.

Under the license agreement, the Germantown, Maryland, company has received exclusive, worldwide rights to make, develop and commercialize technologies utilizing the dissolvable carriers for cell culturing. The technology potentially allows Orgenesis to reduce the cost and complexity of manufacturing its cell therapy programs.

READ: Orgenesis teams up with New York Blood Center for US cell therapy development program

“We are honored to continue our strategic partnership with leading scientists at Ben-Gurion University who have developed this unique dissolvable carrier for cell culturing,” said Orgenesis CEO Vered Caplan. “These breakthrough carriers are the basis for our development of an automated adherent cell culturing system allowing seamless seeding, harvesting and passaging of cells in closed bioreactors. We are excited about the potential of this technology and its abilities to advance adherent cell culturing for cell therapies.”

Professor Smadar Cohen said the Regenerative Medicine and Stem Cell Research Center would work with “skilled” scientists at Orgenesis to accelerate research.

“The research and development of resolvable carriers for cells contains the potential to produce higher quality cells and the technology allows dissolving of carriers and automatic seeding of new ones,” said Cohen. “We believe that Orgenesis has developed a highly scalable and cost-effective platform for cell therapies, which could help accelerate the development of this technology,” said Cohen.

Shares in Orgenesis were up 3.9% to $ 5.35 in morning trading in the US.


Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use